In a May 20 essay in the Washington Post, Steven Petrow takes a look at his sister’s battle with ovarian cancer. He described how, after 18 weeks of chemotherapy, she is faced with a decision: Enroll in clinical trials or sit back in and opt for “active surveillance.”